Latest news with #marketforecast
Reuters
a day ago
- Business
- Reuters
Japan June retail sales rise 2.0% year/year
TOKYO, July 31 (Reuters) - Japanese retail sales rose 2.0% in June from a year earlier, against the median market forecast for a 1.8% rise, government data showed on Thursday. To view full tables, go to the website of the Ministry of Economy, Trade and Industry at: opens new tab
Yahoo
18-07-2025
- Business
- Yahoo
Photonic Quantum Computing to Reach US$6.8 Billion by 2035 - PsiQuantum Leads as Photonic Quantum Vendors Rise
Explore the burgeoning world of Photonic Quantum Computers: these cost-effective, room-temperature machines promise significant growth, with revenues projected to soar from $1.1 billion in 2030 to $6.8 billion by 2035. Get insights on key players like PsiQuantum and market forecasts, covering vendors and components in a booming industry. Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Market for Photonic Quantum Computers" report has been added to offering. Photonic Quantum Computers are quickly emerging as a viable quantum computing platform driven by the belief that they can (1) compute at room temperatures and (2) can be built at low cost using off-the-shelf optical networking components intended for the telecom industry. The primary goal in this report is to analyze and quantify the commercial potential of quantum computers using photonics for their main fabric and to forecast their sales. The report shows how by 2030, worldwide revenues from photonic quantum computers will have reached US$1.1 billion shipped but this number will grow to more than US$6.8 billion by 2035. On the supply side, new firms will be entering the photonic computer market. On the demand side, the demand for quantum computers as a whole will increase dramatically, and this high growth will impact photonic QCs. There are already around 20 vendors commercializing full stack photonic quantum at the present time, with PsiQuantum having attracted the largest funding to date and Xanadu attracting considerable attention too. This report analyzes the product/market strategies of all the manufacturers of full-stack photonic computers including Beijing Bose Quantum, Technology, Mitre Corporation, NTT, ORCA, Photonic, Quickly Quantum, PsiQuantum, QC82, Quandela, Quanfluence, Quantum Computing, Inc., Quantum Source Labs, QuiXQuantum, Rotonium, Tundra Systems, Turing and Xanadu Quantum Technologies. The report also profiles the relevant component, PIC, and software suppliers to the budding photonic quantum systems sector as well as including ten-year forecasts of photonic computer markets. Three types of machines break out the forecasts: "Utility-Class," "HPC/enterprise" machines and "Other" forecasts are provided in both volume and value terms. The report also includes a Chapter on applications for photonic quantum computers, noting where photonic machines are especially favored. Key Topics Covered: Chapter One: Photonic Quantum Computers: Products and Industry Background Background to Report Advantages of Photonic Quantum Computers Challenges of Photonic Quantum Computers Types of Photonic Quantum Computers Chips and Chipsets for Photonic Quantum Computers Research Institutes and Universities Commercial Suppliers Components and Subsystems Lasers and Light Sources Frequency Combs Photon Detectors Control Chips SDKs Novel Architectures for Photonic QCs CV Architectures T Centre architecture The Value QC Brand Communities: Applicability to Photonic QCs Quandela Cloud Xanadu Photonic Quantum Computer Industry Structure Russia and China The Next Chapter Chapter Two: Photonic Quantum Computers and Related Products Bose Quantum Technology/QBoson (China) Current Products Customer Base and Markets Electronics and Telecommunications Research Institute (ETRI) (Korea) InfamousPlatypus (United States) Customer Base and Competition MITRE Corporation/CVE (United States) Quantum Moonshot Customer Base NTT (Japan) Current Research ORCA Computing (United Kingdom) PT Series Products Use of COTS ORCA Customers: Use with HPC Photonic (Canada) Product and Technology Evolution Customer Base and Competition PsiQuantum (United States) Technical Evolution Customer Base and Competition (Germany) QC82 (United States) Goals of the Company Expected Customer Base Quandela Technology and Manufacturing Quandela Cloud Customer Base and Competition Quanfluence (India) Quantum Computing, Inc. United States) Current Products and Services Customer Base and Competition Quantum Source Labs (Israel) Computer Strategy Customer Base QuiX Quantum (The Netherlands) Current Products Customers Rotonium (Italy) Direction of Research and Product Development Manufacturing Possible Customer Base Spooky Manufacturing (United States) TundraSystems Global LTD (United Kingdom) TuringQ (China) Quantum Computer Offerings and Manufacturing Customer Base Xanadu Quantum Technologies (Canada) Products and Technology Manufacturing Customers and Partners The Rise and Fall of Xanadu Cloud Components ID Quantique (Switzerland) M-Labs (China) Menlo Systems (Germany) Nanofiber Quantum Technologies (Japan) Nexus Photonics (United States) Nicslab (United States) Sparrow Quantum (Denmark) Toptica Photonics (Germany) Toshiba (Japan) Vescent (United States) Services Iceberg Quantum (Australia) Software QC Design (Germany) QMware (Switzerland) Platforms qBraid (United States) Research and Universities Centre for Quantum Computation and Communication Technology (CQC2T) (Australia) Griffith University (Australia) Harvard University ( United States) Institute for Photonic Quantum Systems (PhoQC) (Germany) Israeli Quantum Computing Center (IQCC) (Israel) Nanjing University (China) National Quantum Computing Center (NQCC) (United Kingdom) National Quantum Laboratory (NQL) (Russia) Niels Bohr Institute (NBI) (Denmark) Poznan Supercomputing and Networking Center (PSNC) Queensland University of Technology (QUT) (Australia) RIKEN (Japan) Russian Quantum Center (Russia) Sandia National Laboratory (United States) Simon Fraser University (Canada) University of Arizona (United States) University of Bristol (United Kingdom) University of New Mexico (United States) University of Queensland (Australia) University of Science & Technology of China (USTC) University of Southern Queensland (UniSQ) (Australia) University of the Sunshine Coast (Australia) University of Virginia (UVA) (United States) University of Washington (UW) (United States) University of Waterloo (Canada) Chapter Three: Target Applications for Photonic Quantum Computers Research Machines and Laboratories Quantum Chemistry and Materials Science Finance and Banking Military, Intelligence, and Aerospace Automotive and Transportation The Energy Industry Photonic Computers: Design for Specific Locations Photonic Computers and HPC: The Quantum Supercomputer Data Center Scale Photonic Quantum Computers Rack-Mounted Photonic Computers Photonic Quantum Edge Computing Quantum + AI Chapter Four: Ten-Year Forecasts of Photonic Quantum Computers Methodology Shipment Forecast Initial Shipments Growth Over the Next Five Years Shipments by Product Type Alternative Scenarios For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-07-2025
- Health
- Yahoo
MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements
While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders. This evolution signals a potential inflection point, where MCR-targeted drugs could move from orphan exclusivity toward broader commercial and clinical relevance in the coming years. LAS VEGAS, July 14, 2025 /PRNewswire/ -- DelveInsight's MCR Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Obesity due to POMC, PCSK1, or LEPR deficiency, Hypoactive sexual desire disorder (HSDD), Erythropoietic protoporphyria (EPP), Dry Eye Disease, Acquired hypothalamic obesity, Cushing's syndrome, Congenital Adrenal Hyperplasia (CAH), Bardet-Biedl syndrome (BBS), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging MCR therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the MCR Therapies Market Report As per DelveInsight's analysis, the total market size of MCR therapies in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Obesity due to POMC, PCSK1, or LEPR deficiency, Hypoactive sexual desire disorder (HSDD), Erythropoietic protoporphyria (EPP), Dry Eye Disease, Acquired hypothalamic obesity, Cushing's syndrome, Congenital Adrenal Hyperplasia (CAH), Bardet-Biedl syndrome (BBS), and others. Leading MCR therapy companies, such as Palatin Technologies, Rhythm Pharmaceuticals, Crinetics Pharmaceuticals, and others, are developing novel MCR therapies that can be available in the MCR therapies market in the coming years. Some of the key MCR therapies in the pipeline include PL9643, Bivamelagon (LB54640), Atumelnant (CRN04894), and others. In May 2025, Palatin Technologies presented promising Phase III MELODY-1 trial results at ARVO 2025, highlighting breakthrough symptom resolution with PL9643 in patients with dry eye disease. Rhythm Pharmaceuticals reported topline results from its Phase II trial of oral MC4R agonist bivamelagon in its Q1 2025 financial update, also in May 2025. In February 2025, SCENESSE was found to be well tolerated across both adolescent (12–17 years) and adult patients in the CUV052 study for erythropoietic protoporphyria (EPP), with no unexpected safety issues observed. Discover which indication is expected to grab the major MCR therapies market share @ MCR Therapies Market Report MCR Therapies Market Dynamics The MCR therapies market is emerging as a promising therapeutic area, driven by advancements in understanding melanocortin receptor biology and its involvement in multiple disease pathways. MCRs, which include five distinct receptor subtypes (MC1R to MC5R), play crucial roles in regulating inflammation, energy homeostasis, pigmentation, and immune responses. Therapeutics targeting these receptors are being explored across a range of indications including autoimmune diseases, metabolic disorders, dermatological conditions, and ocular diseases. The unique mechanism of MCR agonists, which promote the resolution of inflammation without broad immunosuppression, is positioning them as differentiated options in the crowded anti-inflammatory therapeutics landscape. Market growth is being propelled by a growing pipeline of both small molecule and peptide-based MCR agonists. Companies have made strides in clinical development, particularly in rare diseases such as hypoactive sexual desire disorder and congenital adrenal hyperplasia, as well as common conditions like dry eye disease and inflammatory bowel disease. Successful clinical outcomes and regulatory approvals are anticipated to expand the therapeutic footprint of MCR-targeted agents beyond niche indications. Additionally, partnerships and licensing deals are increasing, reflecting strong pharmaceutical interest in this space. However, the MCR therapies market also faces several challenges. The complex pharmacology of MCR subtypes and their tissue-specific effects complicate the drug development process. Ensuring receptor selectivity and minimizing off-target effects remain critical hurdles, as MCRs are widely expressed in various tissues, and unintended receptor activation could lead to adverse effects. Moreover, as many MCR-targeted therapies are aimed at rare diseases, patient recruitment for clinical trials can be limited, potentially delaying development timelines. Pricing and reimbursement challenges are also expected, particularly in markets where novel therapies are often scrutinized for cost-effectiveness. Despite these challenges, the long-term outlook for the MCR therapies market remains optimistic. Advancements in receptor biology, peptide chemistry, and drug delivery technologies are likely to improve the safety and efficacy profiles of MCR modulators. Additionally, expanding scientific interest in melanocortin pathways' role in neuroinflammation, fibrosis, and cardiometabolic diseases could open up new therapeutic opportunities. As clinical validation accumulates and real-world data supports their utility, MCR-targeted therapies may establish a meaningful niche in the broader anti-inflammatory and immunomodulatory therapeutics markets. MCR Therapies Treatment Market Currently, three therapies targeting melanocortin receptors (MCRs) are approved: IMCIVREE (setmelanotide) from Rhythm Pharmaceuticals, VYLEESI (bremelanotide) from Cosette Pharmaceuticals, and SCENESSE (afamelanotide) from Clinuvel Pharmaceuticals. Together, these drugs form the present therapeutic landscape for MCR-targeted treatments across metabolic disorders, sexual dysfunction, and rare dermatological conditions. IMCIVREE is a selective melanocortin-4 receptor (MC4R) agonist, indicated for chronic weight management in adults and children aged six and older with obesity caused by deficiencies in proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR). Genetic confirmation of pathogenic, likely pathogenic, or uncertain variants in these genes is required for treatment eligibility. Setmelanotide activates the MC4 receptor with much lower activity—approximately 20 times less—at the MC3 and MC1 receptors. MC4 receptors in the brain are critical for regulating appetite, satiety, and energy balance. In people with POMC, PCSK1, or LEPR deficiencies, inadequate MC4 receptor signaling disrupts hunger control and metabolism. By stimulating MC4 receptors, setmelanotide helps normalize this pathway, reducing hunger and promoting weight loss through decreased food intake and increased energy use. Preclinical studies further support MC4R's key role in appetite and weight regulation by setmelanotide. In contrast, the MC1 receptor primarily influences skin pigmentation by regulating melanin synthesis. Setmelanotide is also undergoing Phase II and III trials for various rare genetic and hypothalamic obesity syndromes, including Prader-Willi syndrome, hypothalamic obesity, and other disorders linked to MC4R dysfunction. VYLEESI, another MCR agonist, is approved to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by persistently low sexual desire that causes significant personal distress or relationship issues and is not caused by other medical, psychiatric, or drug-related factors. The active compound in VYLEESI, bremelanotide, activates multiple melanocortin receptor subtypes with the greatest potency at MC1R and MC4R, followed by MC3R, MC5R, and MC2R. At therapeutic doses, its effects are most relevant at MC1R and MC4R. MC4 receptors are widely distributed in the central nervous system and are believed to be involved in modulating sexual desire, although the precise mechanism by which VYLEESI improves HSDD remains unclear. MC1R activation, meanwhile, is known to stimulate melanin production in melanocytes, influencing skin pigmentation. Learn more about the MCR therapies @ MCR Therapies Analysis Key Emerging MCR Therapies and Companies MCR therapies have a robust pipeline across MC1R–MC5R, targeting diverse indications like dry eye disease (PL9643, MC1R/MC5R) and Cushing's syndrome (Atumelnant, MC2R), reflecting broad therapeutic potential in metabolic, inflammatory, and endocrine disorders. PL9643 is a synthetic, topically administered melanocortin receptor (MCR) agonist designed to regulate inflammation on the ocular surface by primarily activating the MC1R and MC5R receptors, which are essential for immune modulation and anti-inflammatory effects. By mimicking the action of natural melanocortins, PL9643 helps resolve inflammation without causing immunosuppression. This distinct mechanism addresses both the inflammatory and neurological aspects of dry eye disease (DED), a complex disorder impacting the tear film and ocular surface. In October 2023, Palatin Technologies announced positive top-line results from the Phase III MELODY-1 study, where PL9643 successfully achieved its primary and several secondary endpoints in patients with moderate to severe DED. In contrast to conventional treatments like corticosteroids and cyclosporine, PL9643 represents a novel, first-in-class melanocortin-based therapeutic approach in ophthalmology. Currently, PL9643 is in Phase III clinical development for moderate to severe dry eye disease, having demonstrated efficacy in the MELODY-1 trial by meeting its primary and secondary goals. The anticipated launch of these emerging therapies are poised to transform the MCR therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the MCR therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about MCR therapies clinical trials, visit @ MCR Therapies Treatment MCR Therapies Overview Melanocortin receptors (MCRs) belong to the G-protein-coupled receptor (GPCR) superfamily, characterized by seven transmembrane domains. Mutagenesis studies have shown that transmembrane regions one, two, three, six, and seven play key roles in ligand binding. So far, five melanocortin receptors (MC1R to MC5R) have been identified and are associated with various human diseases. These receptors are activated by melanocortin peptides such as ACTH, α-MSH, or γ-MSH. Upon activation, melanocortin receptors typically stimulate adenylate cyclase, leading to elevated intracellular levels of cyclic adenosine monophosphate (cAMP), which mediates many of the physiological effects of melanocortins. However, depending on the cell type and which melanocortin receptor is present, other signaling pathways may also be triggered by melanocortin ligands. These include pathways involving increased intracellular calcium via inositol triphosphate, calcium influx from outside the cell, MAP kinase pathways, Janus kinase/STAT signaling, and the protein kinase C pathway. The precise mechanisms through which G-protein-coupled receptors like the melanocortin receptors activate these additional pathways remain unclear, and the effects of MCR antagonists on these alternative pathways have yet to be investigated. MCR Therapies Epidemiology Segmentation The MCR therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases of Selected Indications for MCR Therapies Total Eligible Patient Pool of Selected Indications for MCR Therapies Total Treated Cases of Selected Indications for MCR Therapies MCR Therapies Report Metrics Details Study Period 2020–2034 MCR Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Obesity due to POMC, PCSK1, or LEPR deficiency, Hypoactive sexual desire disorder (HSDD), Erythropoietic protoporphyria (EPP), Dry Eye Disease, Acquired hypothalamic obesity, Cushing's syndrome, Congenital Adrenal Hyperplasia (CAH), Bardet-Biedl syndrome (BBS), and others Key MCR Therapies Companies Palatin Technologies, Rhythm Pharmaceuticals, Crinetics Pharmaceuticals, Cosette Pharmaceuticals, Clinuvel Pharmaceuticals, and others Key MCR Therapies PL9643, Bivamelagon (LB54640), Atumelnant (CRN04894), IMCIVREE, VYLEESI, SCENESSE, and others Scope of the MCR Therapies Market Report MCR Therapies Therapeutic Assessment: MCR Therapies current marketed and emerging therapies MCR Therapies Market Dynamics: Conjoint Analysis of Emerging MCR Therapies Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, MCR Therapies Market Access and Reimbursement Discover more about MCR therapies in development @ MCR Therapies Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary of MCR Therapies 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 MCR Therapies Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies in 2020 6.2 Market Share (%) Distribution by Therapies in 2034 6.3 Market Share (%) Distribution by Indications in 2024 6.4 Market Share (%) Distribution by Indications in 2034 7 MCR Therapies: Background and Overview 7.1 Introduction 7.2 Potential of MCR Therapies in Different Indications 7.3 Clinical Applications of MCR Therapies 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.4 Total Cases in Selected Indications for MCR Therapies in the 7MM 8.5 Total Eligible Patient Pool for MCR Therapies in Selected Indications in the 7MM 8.6 Total Treated Cases in Selected Indications for MCR Therapies in the 7MM 9 Marketed Competitors 9.1 Key Competitors 9.2 IMCIVREE (Setmelanotide): Rhythm Pharmaceuticals 9.2.1 Product Description 9.2.2 Regulatory milestones 9.2.3 Other developmental activities 9.2.4 Clinical development 9.2.5 Safety and efficacy 9.3 VYLEESI (Bremelanotide): Cosette Pharmaceuticals 9.3.1 Product Description 9.3.2 Regulatory milestones 9.3.3 Other developmental activities 9.3.4 Clinical development 9.3.5 Safety and efficacy List to be continued in the report 10 Emerging Therapies 10.1 Key Competitors 10.2 PL9643: Palatin Technologies 10.2.1 Product Description 10.2.2 Other developmental activities 10.2.3 Clinical development 10.2.4 Safety and efficacy List to be continued in the report 11 MCR Therapies: Seven Major Market Analysis 11.1 Key Findings 11.2 Market Outlook 11.3 Conjoint Analysis 11.4 Key Market Forecast Assumptions 11.4.1 Cost Assumptions and Rebates 11.4.2 Pricing Trends 11.4.3 Analogue Assessment 11.4.4 Launch Year and Therapy Uptakes 11.5 Total Market Size of MCR Therapies in the 7MM 11.6 Market Size of MCR Therapies by Indication in the 7MM 11.7 The United States Market Size 11.8 EU4 and the UK Market Size 11.9 Japan Market Size 12 Market Access and Reimbursement 13 SWOT Analysis 14 KOL Views 15 Unmet Needs 16 Bibliography 17 Report Methodology Related Reports Dry Eye Disease Market Dry Eye Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dry eye disease companies, including Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree, RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon, Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A., PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd., Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma, AxeroVision, Inc., AxeroVision, Inc., Glaukos Corporation, Oculis, among others. Obesity Market Obesity Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies, including Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, among others. Congenital Adrenal Hyperplasia Market Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAH companies, including Lundbeck, BridgeBio, Crinetics Pharmaceuticals, Spruce Biosciences, Neurocrine Biosciences, among others. Cushing's Syndrome Market Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakurinfo@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
Yahoo
11-07-2025
- Business
- Yahoo
Synthetic Media Market to Double in Size by 2030: Democratization of Access to Cutting-Edge Tools and Evolving Regulatory Requirements Driving the Industry at 13.41% CAGR
The synthetic media market is set to expand, fueled by AI advancements, democratized content creation tools, and demand for personalized, immersive experiences. Opportunities lie in applying these technologies across sectors such as advertising, education, and healthcare, while addressing regulatory challenges and supply chain shifts. Synthetic Media Market Dublin, July 11, 2025 (GLOBE NEWSWIRE) -- The "Synthetic Media Market by Technology, Content Format, Type, Application, User Base - Global Forecast to 2030" has been added to offering. The Synthetic Media Market is experiencing significant growth, expanding from USD 4.89 billion in 2024 to USD 5.54 billion in 2025, with projections to reach USD 10.42 billion by 2030 at a CAGR of 13.41%. This sector is witnessing a paradigm shift as artificial intelligence, machine learning, and advanced visual technologies come to prominence, revolutionizing how content is created, produced, and consumed. The synthetic media market is driven by rapid technological advancements. The democratization of access to cutting-edge tools, changing economic conditions, and evolving regulatory requirements underpin its growth. Leaders in the field utilize synthetic media to delve deeply into its challenges and opportunities, empowering strategic planning and offering a fresh perspective on content engagement methodologies. Pivotal Transformations Reshaping the Synthetic Media Ecosystem The pace of innovation in synthetic media is swift, particularly in neural network architectures that foster the development of lifelike avatars and dynamic content. This technological stride has seeped into diverse sectors like advertising, entertainment, education, and healthcare. Production tools have become more accessible, encouraging robust participation from startups and individuals alongside major studios. Regulations around deepfakes and intellectual property foster trust, mitigating potential risks. For businesses, leveraging these advancements positions them to harness immersive storytelling and real-time personalization for a competitive advantage. Navigating the Ripple Effects of 2025 United States Tariffs Revised tariffs in the United States for 2025 have prompted a re-evaluation of global supply chains in the synthetic media sector. Elevated costs for computing hardware are leading providers to explore alternative sourcing and edge computing solutions. Trade restrictions have spurred growth in domestic manufacturing and self-reliance in research and development. Concurrently, these changes reshuffle pricing models for software and services, influencing procurement strategies and competitive tactics. Spotlight on Regional Trajectories Across Key Markets Regional insights reveal differing trajectories. North America leads in early adoption due to strong venture capital and infrastructure. Europe focuses on privacy-centric synthetic data innovations, while Asia-Pacific reaps the benefits of rapid digitalization and supportive government initiatives. These insights are crucial for organizations looking to effectively enter and navigate diverse markets, crafting strategies that align with regional trends. Strategic Movements and Profiles of Leading Innovators Key industry innovators, like OpenAI and NVIDIA, are transforming the synthetic media landscape with groundbreaking models and technology expansions. Adobe and meta-collaborations signify a dedicated move toward metaverse developments, positioning themselves advantageously within this burgeoning field. This section offers strategic insights that benefit firms in enhancing operational efficiency and competitiveness. Proactive Strategies to Seize Emerging Synthetic Media Opportunities Success in synthetic media requires embedding it into core strategies, supported by interdisciplinary teams adept in both creative and data sciences. Prototyping labs, ethical governance, and strategic partnerships broaden opportunities for breakthroughs and resilience against uncertainties like policy shifts. Flexible commercial models further align vendor incentives with business goals, assuring sustainable growth. Key Takeaways from This Report Expectation of market growth to USD 10.42 billion by 2030 highlights significant opportunities for stakeholders. Technological advancements democratizing the production landscape, offering smaller players opportunities alongside major entities. Revised U.S. tariffs impacting strategies but encouraging innovative sourcing and logistics solutions. Regional and technological segmentation provides granular insights essential for market entry or expansion strategies. The companies profiled in this Synthetic Media market report include: Adobe Inc. Amazon Web Services, Inc. Cluep Inc. Colossyan Creator Converseon, Inc. Deep Voodoo Deepbrain AI Google LLC by Alphabet Inc. Hootsuite Inc. International Business Machines Corporation iProov Meltwater Meta Platforms, Inc. Midjourney NetBase Quid OpusClip Pareto, inc. Rask AI Salesforce, Inc. SensorTower, Inc. Sprinklr, Inc. Sprout Social, Inc. SYNTAX + MOTION Synthesia Limited Unmetric Key Attributes Report Attribute Details No. of Pages 195 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $5.54 Billion Forecasted Market Value (USD) by 2030 $10.42 Billion Compound Annual Growth Rate 13.4% Regions Covered Global Key Topics Covered1. Preface1.1. Objectives of the Study1.2. Market Segmentation & Coverage1.3. Years Considered for the Study1.4. Currency & Pricing1.5. Language1.6. Stakeholders2. Research Methodology2.1. Define: Research Objective2.2. Determine: Research Design2.3. Prepare: Research Instrument2.4. Collect: Data Source2.5. Analyze: Data Interpretation2.6. Formulate: Data Verification2.7. Publish: Research Report2.8. Repeat: Report Update3. Executive Summary4. Market Overview4.1. Introduction4.2. Market Sizing & Forecasting5. Market Dynamics6. Market Insights6.1. Porter's Five Forces Analysis6.2. PESTLE Analysis7. Cumulative Impact of United States Tariffs 20258. Synthetic Media Market, by Technology8.1. Introduction8.2. Artificial Intelligence & Machine Learning8.3. Augmented Reality & Virtual Reality8.4. Computer Graphics & Visual Effects8.5. Generative Adversarial Networks8.6. Natural Language Processing8.7. Voice Synthesis & Recognition9. Synthetic Media Market, by Content Format9.1. Introduction9.2. Interactive Content9.2.1. Choose-your-own-adventure Stories9.2.2. Virtual Reality Experiences9.3. Long Form Content9.3.1. Documentaries9.3.2. Podcast Episodes9.4. Short Form Content9.4.1. Animated GIFs9.4.2. Social Media Posts10. Synthetic Media Market, by Type10.1. Introduction10.2. Text-to-Image10.3. Text-to-Video10.4. Voice Synthesis & Modification11. Synthetic Media Market, by Application11.1. Introduction11.2. Customer Service11.3. Education11.3.1. Interactive Learning11.3.2. Virtual Lectures11.4. Entertainment & Media11.4.1. Films & Movies11.4.2. Music & Albums11.5. Healthcare11.6. Marketing & Advertising11.6.1. Banner & Graphic Design11.6.2. Campaign Creation12. Synthetic Media Market, by User Base12.1. Introduction12.2. Corporate Entities12.2.1. Digital Marketing Agencies12.2.2. Media Production Houses12.3. Educational Institutions12.3.1. Online Learning Platforms12.3.2. Universities12.4. Individual Creators12.4.1. Freelancers12.4.2. Independent Artists13. Americas Synthetic Media Market13.1. Introduction13.2. United States13.3. Canada13.4. Mexico13.5. Brazil13.6. Argentina14. Europe, Middle East & Africa Synthetic Media Market14.1. Introduction14.2. United Kingdom14.3. Germany14.4. France14.5. Russia14.6. Italy14.7. Spain14.8. United Arab Emirates14.9. Saudi Arabia14.10. South Africa14.11. Denmark14.12. Netherlands14.13. Qatar14.14. Finland14.15. Sweden14.16. Nigeria14.17. Egypt14.18. Turkey14.19. Israel14.20. Norway14.21. Poland14.22. Switzerland15. Asia-Pacific Synthetic Media Market15.1. Introduction15.2. China15.3. India15.4. Japan15.5. Australia15.6. South Korea15.7. Indonesia15.8. Thailand15.9. Philippines15.10. Malaysia15.11. Singapore15.12. Vietnam15.13. Taiwan16. Competitive Landscape16.1. Market Share Analysis, 202416.2. FPNV Positioning Matrix, 202416.3. Competitive Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Synthetic Media Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Globe and Mail
30-06-2025
- Business
- Globe and Mail
GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim
DelveInsight's 'CTD-ILD Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the CTD-ILD, historical and forecasted epidemiology as well as the CTD-ILD market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of CTD-ILD, offering comprehensive insights into the CTD-ILD revenue trends, prevalence, and treatment landscape. The report delves into key CTD-ILD statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CTD-ILD therapies. Additionally, we cover the landscape of CTD-ILD clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CTD-ILD treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CTD-ILD space. The CTD-ILD market size was valued ~USD 1,498 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In 2023, the United States held the largest market share for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), contributing approximately 70% of the total market size across the 7MM. This was significantly higher compared to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2023, Germany recorded the largest market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) among EU countries, reaching nearly USD 84 million, while Spain had the smallest market size at USD 38 million. Japan's market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) was approximately USD 136 million in 2023, representing 9% of the total market across the 7MM. Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others The CTD-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CTD-ILD pipeline products will significantly revolutionize the CTD-ILD market dynamics. According to DelveInsight's evaluation, the total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM were approximately 1,662,000 in 2023. In 2023, the United States recorded the highest number of diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), approximately 132,000, with numbers anticipated to increase in the future. Within Europe, the UK reported the highest number of diagnosed prevalent cases of CTD-ILD in 2023, approximately 27,000, followed by Germany with 25,000 cases. In contrast, Spain had the lowest prevalence, with around 11,000 cases. In 2023, Japan reported approximately 68,000 diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), representing around 23% of the total cases across the 7MM. In the US in 2023, type-specific diagnosed cases of CTD-ILD were highest for pSS-ILD (approximately 38,000), followed by SSc-ILD (around 31,000), Other CTD-ILDs (roughly 30,000), RA-ILD (about 20,000), DM-ILD/PM-ILD (close to 8,000), and SLE-ILD (nearly 5,000). Connective Tissue Disease associated with Interstitial Lung Disease Overview Connective Tissue Disease (CTD)-associated Interstitial Lung Disease (ILD) refers to a group of lung disorders that occur as a result of underlying connective tissue diseases. These diseases, such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and polymyositis, can cause inflammation and scarring in the lungs, leading to ILD. This condition results in impaired lung function, breathing difficulties, and decreased oxygen levels. The damage is often progressive and can lead to respiratory failure if left untreated. Early diagnosis and management are crucial to managing symptoms and slowing disease progression. Treatment typically involves immunosuppressive medications and management of the underlying CTD. CTD-ILD Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Segmentation: The CTD-ILD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving CTD-ILD epidemiology trends @ CTD-ILD Epidemiology Forecast CTD-ILD Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CTD-ILD market or expected to get launched during the study period. The analysis covers CTD-ILD market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the CTD-ILD Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. CTD-ILD Therapies and Key Companies Belimumab: GlaxoSmithKline bosentan: Actelion Tulisokibart: Prometheus Biosciences Rituximab: Eric Matteson Vixarelimab: Genentech, Inc. OFEV: Boehringer Ingelheim Pharmaceuticals, Inc. Belimumab, GSK1550188 (BENLYSTA): GlaxoSmithKline plc. Connective Tissue Disease associated with Interstitial Lung Disease Market Drivers Increasing Prevalence of CTD-ILD Advances in Diagnostic Techniques Emergence of Novel Therapies Rising Awareness Among Healthcare Providers Aging Population Regulatory Approvals for Targeted Treatments Supportive Healthcare Policies Connective Tissue Disease associated with Interstitial Lung Disease Market Barriers High Cost of Treatment Limited Drug Approvals Challenges in Early Diagnosis Heterogeneity of CTD-ILD Side Effects of Current Treatments Lack of Awareness in Emerging Markets Inconsistent Clinical Guidelines Scope of the Connective Tissue Disease associated with Interstitial Lung Disease Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others CTD-ILD Therapeutic Assessment: CTD-ILD current marketed and CTD-ILD emerging therapies CTD-ILD Market Dynamics: CTD-ILD market drivers and CTD-ILD market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Table of Contents 1. CTD-ILD Market Report Introduction 2. Executive Summary for CTD-ILD 3. SWOT analysis of CTD-ILD 4. CTD-ILD Patient Share (%) Overview at a Glance 5. CTD-ILD Market Overview at a Glance 6. CTD-ILD Disease Background and Overview 7. CTD-ILD Epidemiology and Patient Population 8. Country-Specific Patient Population of CTD-ILD 9. CTD-ILD Current Treatment and Medical Practices 10. CTD-ILD Unmet Needs 11. CTD-ILD Emerging Therapies 12. CTD-ILD Market Outlook 13. Country-Wise CTD-ILD Market Analysis (2020–2034) 14. CTD-ILD Market Access and Reimbursement of Therapies 15. CTD-ILD Market Drivers 16. CTD-ILD Market Barriers 17. CTD-ILD Appendix 18. CTD-ILD Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
